An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women
- PMID: 22579434
- PMCID: PMC3351689
- DOI: 10.1016/j.ctim.2012.03.001
An investigation of the possible interaction between the use of Vitamin C and highly active antiretroviral therapy (HAART) adherence and effectiveness in treated HIV+ women
Abstract
Objectives: Our goal in this study was to examine how Vitamin C interacts with antiretroviral therapy in individuals with HIV. We specifically evaluated how Vitamin C impacts highly active antiretroviral therapy (HAART) adherence and HAART effectiveness as adjudicated by HIV viral loads and CD4 cell counts. Women served as their own controls, comparing periods of Vitamin C usage with periods of non-usage.
Design: An intra-individual, cross-sectional comparative study 'nested' in the WIHS observational cohort study.
Subjects: Women in the Women's Interagency HIV Study (WIHS).
Outcome measures: Adherence, CD4 count and viral load.
Results: Our study population was drawn from 2813 HIV+ participants who contributed 44,588 visits in WIHS from October, 1994 to April, 2009. Among them, there were 1122 Vitamin C users with 4954 total visits where use was reported. In the multivariate model adjusting for age, education, race, income, drug use, Vitamin C use order and depression score, there was a 44% increase in the odds of ≥ 95% HAART adherence among participants during their period of Vitamin C use compared to when they were not using Vitamin C (OR=1.44; 95% CI=1.1-1.9; P-value=0.0179). There was an association with Vitamin C usage and CD4 counts on viral loads.
Conclusion: Vitamin C usage appears to be associated with improved adherence. Future Vitamin C studies should target specific HAART drugs, and prospective clinical outcomes.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of Interest Statement:
None declared.
References
-
- Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, et al. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract. 2006;12:34–9. - PubMed
-
- Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:1548–53. - PubMed
-
- Stern RC, Canda ER, Doershuk CF. Use of nonmedical treatment by cystic fibrosis patients. J Adolesc Health. 1992;13:612–5. - PubMed
-
- Southwood TR, Malleson PN, Roberts-Thomson PJ, Mahy M. Unconventional remedies used for patients with juvenile arthritis. Pediatrics. 1990;85:150–4. - PubMed
-
- Digianni LM, Rue M, Emmons K, Garber JE. Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiol Biomarkers Prev. 2006;15:70–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UO1-HD-32632/HD/NICHD NIH HHS/United States
- UO1-AI-34994/AI/NIAID NIH HHS/United States
- UO1-AI-34989/AI/NIAID NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- UO1-AI-35004/AI/NIAID NIH HHS/United States
- UO1-AI-34993/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- UO1-AI-42590/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- UO1-AI-31834/AI/NIAID NIH HHS/United States
- 3U01AI034994-16S/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
